Xeris Biopharma Tightens 2023 Revenue Guidance From $155M-$165M To $160M-$165M
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has revised its 2023 revenue guidance from a range of $155M-$165M to a narrower range of $160M-$165M.
November 09, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma has updated its 2023 revenue guidance, indicating a potential increase in future revenues.
The revision of the revenue guidance by Xeris Biopharma indicates a potential increase in future revenues. This could be seen as a positive signal by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100